Increased protection from vaccinia virus infection in mice genetically prone to lymphoproliferative disorders

Journal of Virology

Volumn 86, Issue 11, 2012, Pages 6010-6022

  Seedhom, Mina O ^a,d   Mathurin, Keisha S ^a,c   Kim, Sung Kwon ^a,b   Welsh, Raymond M ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c ASTEX PHARMACEUTICALS   (United Kingdom)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; GAMMA INTERFERON; HERMES ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; FAS GENE; GENE MUTATION; GENETIC RISK; IMMUNOMODULATION; IMMUNOREACTIVITY; INFECTION RESISTANCE; INFECTION SENSITIVITY; LEUKOCYTE ACTIVATION; LIVER PARENCHYMA; LYMPHOPROLIFERATIVE DISEASE; MOUSE; MOUSE MUTANT; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN; T CELL DEPLETION; T LYMPHOCYTE SUBPOPULATION; VACCINIA; VACCINIA VIRUS; VIRAL CLEARANCE; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS LOAD; VIRUS TITRATION; ANIMAL; C57BL MOUSE; CD4+ T LYMPHOCYTE; DISEASE RESISTANCE; GENETICS; IMMUNOLOGY; LIVER; LYMPHOCYTE SUBPOPULATION; MORTALITY; PATHOGENICITY; SECRETION; SURVIVAL; VIROLOGY;

MUS; VACCINIA VIRUS;

ANIMALS; ANTIGENS, CD95; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE RESISTANCE; INTERFERON-GAMMA; LIVER; LYMPHOCYTE SUBSETS; LYMPHOPROLIFERATIVE DISORDERS; MICE; MICE, INBRED C57BL; SPLEEN; SURVIVAL ANALYSIS; VACCINIA; VACCINIA VIRUS; VIRAL LOAD;

EID: 84863579077     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.07176-11     Document Type: Article

References (71)

1. Andrews BS, et al. 1978. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J. Exp. Med. 148:1198-1215.
2. Arase H, Arase N, Saito T. 1995. Fas-mediated cytotoxicity by freshly isolated natural killer cells. J. Exp. Med. 181:1235-1238.
3. Belyakov IM, et al. 2003. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc. Natl. Acad. Sci. U. S. A. 100:9458-9463.
4. Boyer MH, Hoff R, Kipnis TL, Murphy ED, Roths JB. 1983. Trypanosoma cruzi: susceptibility in mice carrying mutant gene lpr (lymphoproliferation). Parasite Immunol. 5:135-142.
5. Budd RC, Schumacher JH, Winslow G, Mosmann TR. 1991. Elevated production of interferon-gamma and interleukin 4 by mature T cells from autoimmune lpr mice correlates with Pgp-1 (CD44) expression. Eur. J. Immunol. 21:1081-1084.
6. Bukowski JF, Woda BA, Habu S, Okumura K, Welsh RM. 1983. Natural killer cell depletion enhances virus synthesis and virus-induced hepatitis in vivo. J. Immunol. 131:1531-1538.
7. Cantin E, Tanamachi B, Openshaw H, Mann J, Clarke K. 1999. Gamma interferon (IFN-gamma) receptor null-mutant mice are more susceptible to herpes simplex virus type 1 infection than IFN-gamma ligand nullmutant mice. J. Virol. 73:5196.
8. Chatterjee K, et al. 2010. A Fas gene polymorphism influences herpes simplex virus type 2 infection in South African women. J. Med. Virol. 82:2082-2086.
9. Cheney IW, et al. 2002. Comparative analysis of anti-hepatitis C virus activity and gene expression mediated by alpha, beta, and gamma interferons. J. Virol. 76:11148-11154.
10. Davidson WF, Dumont FJ, Bedigian HG, Fowlkes BJ, Morse HC III. 1986. Phenotypic, functional, and molecular genetic comparisons of the abnormal lymphoid cells of C3H-lpr/lpr and C3H-gld/gld mice. J. Immunol. 136:4075-4084.
11. +T cells requires gamma interferon and either perforin- or Fas-mediated cytolytic mechanisms. J. Virol. 79: 14546-14554.
12. Fang M, Lanier L, Sigal L. 2008. A role for NKG2D in NK cell-mediated resistance to poxvirus disease. PLoS Pathog. 4:e30.
13. Farre L, et al. 2008. Fas 670 promoter polymorphism is associated to susceptibility, clinical presentation, and survival in adult T cell leukemia. J. Leukoc. Biol. 83:220-222.
14. Frese M, et al. 2002. Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 35:694-703.
15. Hiramatsu N, et al. 1994. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 19:1354-1359.
16. Horiuchi T, et al. 1999. Association of Fas/APO-1 gene polymorphism with systemic lupus erythematosus in Japanese. Rheumatology (Oxford) 38:516-520.
17. Hu MS, et al. 1999. Fas-FasL interaction involved in pathogenesis of ocular toxoplasmosis in mice. Infect. Immun. 67:928-935.
18. Huang FP, et al. 1998. Mice defective in Fas are highly susceptible to Leishmania major infection despite elevated IL-12 synthesis, strong Th1 responses, and enhanced nitric oxide production. J. Immunol. 160:4143-4147.
19. Huang QR, Morris D, Manolios N. 1997. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol. Immunol. 34:577-582.
20. Huang S, et al. 1993. Immune response in mice that lack the interferongamma receptor. Science 259:1742-1745.
21. Ishikawa T, et al. 2009. Protective role of Fas-FasL signaling in lethal infection with herpes simplex virus type 2 in mice. J. Virol. 83:11777-11783.
22. + T-cell involvement in clearance of infectious herpes simplex virus type 1 from sensory ganglia and spinal cords. J. Virol. 82:9678-9688.
23. + cytotoxic T cells. Proc. Natl. Acad. Sci. U. S. A. 91:4185-4189.
24. Jung YJ, et al. 2007. Putative association of Fas and FasL gene polymorphisms with clinical outcomes of hepatitis B virus infection. Intervirology 50:369-376.
25. Kagi D, et al. 1995. The roles of perforin- and Fas-dependent cytotoxicity in protection against cytopathic and noncytopathic viruses. Eur. J. Immunol. 25:3256-3262.
26. Kanemitsu S, et al. 2002. A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J. Rheumatol. 29:1183-1188.
27. Karupiah G, Fredrickson T, Holmes K, Khairallah L, Buller R. 1993. Importance of interferons in recovery from mousepox. J. Virol. 67:4214.
28. Kawakami Y, et al. 2009. Inhibition of NK cell activity by IL-17 allows vaccinia virus to induce severe skin lesions in a mouse model of eczema vaccinatum. J. Exp. Med. 206:1219-1225.
29. Kettle S, et al. 1997. Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1beta-converting enzyme and protects virus-infected cells from TNFand Fas-mediated apoptosis, but does not prevent IL-1beta-induced fever. J. Gen. Virol. 78:677-685.
30. Ksiaa Cheikhrouhou L, et al. 2011. Cytokine and apoptosis gene polymorphisms influence the outcome of hepatitis C virus infection. Hepatobiliary Pancreat. Dis. Int. 10:280-288.
31. + T cell responses through regulated FasL expression. Immunity 23:649-659.
32. Lohman BL, Razvi ES, Welsh RM. 1996. T-lymphocyte downregulation after acute viral infection is not dependent on CD95 (Fas) receptor-ligand interactions. J. Virol. 70:8199-8203.
33. Lopes MF, et al. 1999. Increased susceptibility of Fas ligand-deficient gld mice to Trypanosoma cruzi infection due to a Th2-biased host immune response. Eur. J. Immunol. 29:81-89.
34. Lyons AB, Parish CR. 1994. Determination of lymphocyte division by flow cytometry. J. Immunol. Methods 171:131-137.
35. Martinez J, Huang X, Yang Y. 2008. Direct action of type I IFN on NK cells is required for their activation in response to vaccinia viral infection in vivo. J. Immunol. 180:1592.
36. Milligan GN, Bernstein DI. 1997. Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract. Virology 229:259-268.
37. Morse HC, III, et al. 1985. Abnormalities induced by the mutant gene, lpr. Patterns of disease and expression of murine leukemia viruses in SJL/J. mice homozygous and heterozygous for lpr. J. Exp. Med. 161:602-616.
38. Mosbach-Ozmen L, Fonteneau P, Loor F. 1985. The C57BL/6 nu/nu lpr/lpr mouse. I. Expression of the 'lpr phenotype' in the C57BL/6 genetic background. Thymus 7:221.
39. Moskophidis D, Lechner F, Pircher H, Zinkernagel RM. 1993. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 362:758-761.
40. +T cell count after antiretroviral therapy in drug-naive HIV-positive patients. Immunogenetics 57:628-635.
41. Netea MG, van Der Meer JW, Meis JF, Kullberg BJ. 1999. Fas-FasL interactions modulate host defense against systemic Candida albicans infection. J. Infect. Dis. 180:1648-1655.
42. Oliveira JB, et al. 2010. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood 116:e35- e40.
43. Parra B, et al. 2000. Contributions of Fas-Fas ligand interactions to the pathogenesis of mouse hepatitis virus in the central nervous system. J. Virol. 74:2447-2450.
44. Razvi ES, Welsh RM. 1993. Programmed cell death of T lymphocytes during acute viral infection: a mechanism for virus-induced immune deficiency. J. Virol. 67:5754-5765.
45. Roths JB, Murphy ED, Eicher EM. 1984. A new mutation, gld, that produces lymphoproliferation and autoimmunity in C3H/HeJ mice. J. Exp. Med. 159:1-20.
46. +)-independent T cell-mediated cytotoxicity. J. Exp. Med. 177:195-200.
47. + T cells is dependent on interferon-gamma. Lymphokine Cytokine Res. 10:353-358.
48. Russell J, Rush B, Weaver C, Wang R. 1993. Mature T cells of autoimmune lpr/lpr mice have a defect in antigen-stimulated suicide. Proc. Natl. Acad. Sci. U. S. A. 90:4409.
49. Russell JH, Wang R. 1993. Autoimmune gld mutation uncouples suicide and cytokine/proliferation pathways in activated, mature T cells. Eur. J. Immunol. 23:2379-2382.
50. Russell JH, White CL, Loh DY, Meleedy-Rey P. 1991. Receptorstimulated death pathway is opened by antigen in mature T cells. Proc. Natl. Acad. Sci. U. S. A. 88:2151-2155.
51. Selin L, Santolucito P, Pinto A, Szomolanyi-Tsuda E, Welsh R. 2001. Innate immunity to viruses: control of vaccinia virus infection by {gamma} {delta} T cells. J. Immunol. 166:6784.
52. Selin LK, Varga SM, Wong IC, Welsh RM. 1998. Protective heterologous antiviral immunity and enhanced immunopathogenesis mediated by memory T cell populations. J. Exp. Med. 188:1705-1715.
53. Shi C, et al. 2006. Fas ligand deficiency impairs host inflammatory response against infection with the spirochete Borrelia burgdorferi. Infect. Immun. 74:1156-1160.
54. + T-cell-mediated control of West Nile virus infection in the central nervous system. J. Virol. 81:11749-11757.
55. Sibley K, et al. 2003. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res. 63: 4327-4330.
56. Suda T, Takahashi T, Golstein P, Nagata S. 1993. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75:1169-1178.
57. Takahashi S, Maecker HT, Levy R. 1989. DNA fragmentation and cell death mediated by T cell antigen receptor/CD3 complex on a leukemia T cell line. Eur. J. Immunol. 19:1911-1919.
58. Takahashi T, et al. 1994. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76:969-976.
59. Taylor JM, Barry M. 2006. Near death experiences: poxvirus regulation of apoptotic death. Virology 344:139-150.
60. + T cells clear influenza virus by perforin or Fas-dependent processes. J. Immunol. 159:5197-5200.
61. Ucker DS, Ashwell JD, Nickas G. 1989. Activation-driven T cell death. I. Requirements for de novo transcription and translation and association with genome fragmentation. J. Immunol. 143:3461-3469.
62. Umland S, Lee R, Howard M, Martens C. 1989. Expression of lymphokine genes in splenic lymphocytes of autoimmune mice. Mol. Immunol. 26:649-656.
63. + T cells during acute infection with lymphocytic choriomeningitis virus. J. Immunol. 161:3215-3218.
64. Wasilenko ST, Meyers AF, Vander Helm K, Barry M. 2001. Vaccinia virus infection disarms the mitochondrion-mediated pathway of the apoptotic cascade by modulating the permeability transition pore. J. Virol. 75:11437-11448.
65. Wasilenko ST, Stewart TL, Meyers AF, Barry M. 2003. Vaccinia virus encodes a previously uncharacterized mitochondrial-associated inhibitor of apoptosis. Proc. Natl. Acad. Sci. U. S. A. 100:14345-14350.
66. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. 1992. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314-317.
67. Wells AD, Gudmundsdottir H, Turka LA. 1997. Following the fate of individual T cells throughout activation and clonal expansion. Signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response. J. Clin. Invest. 100:3173-3183.
68. Wu J, et al. 2003. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J. Immunol. 170:132-138.
69. Wu J, et al. 1996. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J. Clin. Invest. 98:1107-1113.
70. Xu R, Johnson A, Liggitt D, Bevan M. 2004. Cellular and humoral immunity against vaccinia virus infection of mice. J. Immunol. 172:6265.
71. Yang HY, Dundon PL, Nahill SR, Welsh RM. 1989. Virus-induced polyclonal cytotoxic T lymphocyte stimulation. J. Immunol. 142:1710-1718.